Skip to main content

Advertisement

Table 1 Clinical characteristics associated with PRAF2 mRNA expression

From: PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma

Characteristics All patients PRAF2 level Overall survival
Low High P value mOS (95% CI) P value
Patients, No. 77 41 36    
Age, y
  ≤ 60 34 16 18 0.366 28.0 (16.7–39.3) 0.144
  > 60 43 25 18   26.0 (17.0–35.0)  
Gender
 Males 59 34 25 0.166 28.0 (22.2–33.8) 0.234
 Females 18 7 11   22.0 (20.2–23.8)  
Location
 Up 10 3 7 0.192 29.0 (13.4–38.6) 0.624
 Middle 45 25 20   26.8 (19.5–34.0)  
 Low 22 13 9   30.0 (14.1–45.9)  
G stage
 G1 21 16 5 0.049* 36.0 (20.1–33.9) 0.009*
 G2 45 20 25   22.0 (11.1–32.9)  
 G3 11 5 6   17.3 (12.3–22.4)  
TNM stage
 I 4 4 0 0.009* 25 0.010*
 II 52 31 21   30.0 (23.7–36.3)  
 III 21 6 15   20.0 (15.2–24.8)  
PRAF2 level
 Low      33.0 (24.2–41.8) < 0.001*
 High      20.0 (16.3–23.6)  
  1. mOS median overall survival, y years, G differentiation grade. *P < 0.05 indicates significant correlation